A top-down approach for construction of hybrid polymer-virus gene delivery vectors.
Safe and efficient delivery of therapeutic nucleic acids remains the primary hurdle for human gene therapy. While many researchers have attempted to re-engineer viruses to be suited for gene delivery, others have sought to develop non-viral alternatives. We have developed a complementary approach in which viral and synthetic components are combined to form hybrid nanoparticulate vectors. In particular, we complexed non-infectious retrovirus-like particles lacking a viral envelope protein, from Moloney murine leukemia virus (M-VLP) or human immunodeficiency virus (H-VLP), with poly-L-lysine (PLL) or polyethylenimine (PEI) over a range of polymer/VLP ratios. At appropriate stoichiometry (75-250 microg polymer/10(6) VLP), the polymers replace the function of the viral envelope protein and interact with the target cell membrane, initiate cellular uptake and facilitate escape from endocytic vesicles. The viral particle, once in the cytosol, efficiently completes its normal infection process including integration of viral genes with the host genome as demonstrated by long-term (at least 5 weeks) transgene expression. In addition, hybrid vectors comprising H-VLP were shown to be capable of infecting non-dividing cells.
Ramsey
Joshua D
JD
Department of Chemical and Biomolecular Engineering, University of Illinois, Urbana, IL 61801, USA.
Vu
Halong N
HN
Pack
Daniel W
DW
D002678:Chimera; D018014:Gene Transfer Techniques; D005814:Genes, Viral; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008239:Lysine / Q000235:genetics; D008979:Moloney murine leukemia virus / Q000235:genetics; D011094:Polyethyleneimine; D011108:Polymers; D019076:Transgenes; D014759:Viral Envelope Proteins / Q000235:genetics; D014771:Virion / Q000235:genetics; D014777:Virus Diseases / Q000235:genetics; D014780:Viruses / Q000235:genetics
D011108:Polymers; D014759:Viral Envelope Proteins; D011094:Polyethyleneimine; D008239:Lysine